Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06580002
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-28
Brief Title:
Repurposing Riluzole for Cancer-Related Cognitive Impairment a Pilot Trial
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor BDNF Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment an Interventional Pilot Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 2a randomized double-blinded placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor BDNF levels of breast cancer survivors with cancer related cognitive impairment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None